-+ 0.00%
-+ 0.00%
-+ 0.00%

Kang Fang Biology (09926): Abnormal stock price fluctuations are unknown to any reason for the price fluctuation

Zhitongcaijing·11/16/2026 04:41:04
Listen to the news

Zhitong Finance App News, Kang Fang Biotech (09926) issued an announcement. The company took note of the press release issued by Summit Therapeutics Inc. (NASDAQ: SMMT) on November 15, 2026, regarding the receipt of a full response letter (CRL) from the US Food and Drug Administration regarding its application for marketing approval of ivonescimab (ivonescimab) biological products submitted based on the Harmoni study.

After making inquiries that were reasonable for the Company in the circumstances, the Company confirmed that apart from the CRL mentioned above, which may cause abnormal fluctuations in the price of the Company's shares, the Board of Directors is unaware of any reason for the price fluctuation, nor is it aware of any information that must be disclosed to avoid false markets in the Company's securities, or any insider information required to be disclosed in accordance with Part XIVA of the Securities and Futures Ordinance.